+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure assessment of reduction in mortality and morbidity programme



Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure assessment of reduction in mortality and morbidity programme



European Heart Journal: 21, 2641-2650



Aims: The curiosity that leanness is associated with poor survival in patients with chronic heart failure (CHF) needs further insight by investigating the impact of weight loss on prognosis in a large sample of patients across a broad spectrum of both reduced and preserved left ventricular (LV) systolic function.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 034231126

Download citation: RISBibTeXText

DOI: 10.1093/eurheartj/ehn420


Related references

Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Heart Journal 29(21): 2641-2650, 2008

Candesartan improves functional class across a broad spectrum of patients with chronic heart failure Results of the candesartan in heart failure-assessment of reduction in mortality and morbidity programme. Journal of the American College of Cardiology 43(5 Suppl. A): 206A, March 3, 2004

Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure 12(7): 738-745, 2010

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Archives of Internal Medicine 168(15): 1699-1704, 2008

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Yearbook of Cardiology 2007: 449-450, 2007

Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. American Heart Journal 152(1): 86-92, 2006

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. European Heart Journal 29(24): 3022-3028, 2009

Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. Journal of Hypertension. Suppl. 24(1): S3-S7, 2006

Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. European Journal of Heart Failure 7(4): 650-656, 2005

Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. European Journal of Heart Failure 17(2): 196-204, 2015

Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110(15): 2180-2183, 2004

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal 29(11): 1377-1385, 2008

Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. Journal of the American College of Cardiology 59(20): 1785-1795, 2012

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Journal of Heart Failure 5(3): 261-270, 2003

Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 32(5): 915-920, 2009